{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:20:25Z","timestamp":1790882425918,"version":"4.1.0"},"reference-count":102,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Gemcitabine-based chemotherapy is the current standard treatment for biliary tract cancers (BTCs) and resistance to gemcitabine remains the clinical challenge. TP53 mutation has been shown to be associated with poor clinicopathologic characteristics and survival in patients with BTCs, indicating that p53 plays an important role in the treatment of these cancers. Herein, we comprehensively reviewed previous BTC preclinical research and early clinical trials in terms of p53, as well as novel p53-targeted treatment, alone or in combination with either chemotherapy or other targeted therapies in BTCs. Preclinical studies have demonstrated that p53 mutations in BTCs are associated with enhanced gemcitabine resistance, therefore targeting p53 may be a novel therapeutic strategy for treatment of BTCs. Directly targeting mutant p53 by p53 activators, or indirectly by targeting cell cycle checkpoint proteins (Chk1, ataxia telangiectasia related (ATR), and Wee1) leading to synthetic lethality, may be potential future strategies for gemcitabine-resistant p53 mutated BTCs. In contrast, for wild-type p53 BTCs, activation of p53 by inhibition of its negative regulators (MDM2 and wild-type p53-induced phosphatase 1 (WIP1)) may be alternative options. Combination therapies consisting of standard cytotoxic drugs and novel small molecules targeting p53 and related signaling pathways may be the future key standard approach to beat cancer.<\/jats:p>","DOI":"10.3390\/biom10111474","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T08:59:28Z","timestamp":1603443568000},"page":"1474","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-8805","authenticated-orcid":false,"given":"Chiao-En","family":"Wu","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-2674","authenticated-orcid":false,"given":"Yi-Ru","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Liver Research Center, Chang Gung Memorial Hospital, Linkou branch, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of General Surgery and Liver Research Center, Chang Gung Memorial Hospital, Linkou branch, Chang Gung University, Taoyuan 333, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lunec","sequence":"additional","affiliation":[{"name":"Newcastle University Cancer Centre, Bioscience Institute, Medical Faculty, Newcastle University, Newcastle upon Tyne NE2 4HH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.3748\/wjg.14.6458","article-title":"Cholangiocarcinoma: A compact review of the literature","volume":"14","author":"Ustundag","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(05)67530-7","article-title":"Cholangiocarcinoma","volume":"366","author":"Khan","year":"2005","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wu, C.E., Chen, M.H., and Yeh, C.N. (2019). mTOR Inhibitors in Advanced Biliary Tract Cancers. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030500"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","article-title":"The epidemiology of cholangiocarcinoma","volume":"24","author":"Shaib","year":"2004","journal-title":"Semin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Wu, C.E. (2020). Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: A real-world experience. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-06914-1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2009.27.4787","article-title":"Genetics of Biliary Tract Cancers and Emerging Targeted Therapies","volume":"28","author":"Hezel","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/hep.24145","article-title":"Development of Molecularly Targeted Therapies in Biliary Tract Cancers: Reassessing the Challenges and Opportunities","volume":"53","author":"Zhu","year":"2011","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"324","DOI":"10.21037\/jgo.2016.09.16","article-title":"Targeted therapy in biliary tract cancers-current limitations and potentials in the future","volume":"8","author":"Sahu","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: A multicentre, open-label, randomised, phase 3 study","volume":"13","author":"Lee","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): A randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"Malka","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): A randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"Chen","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cncr.29778","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","volume":"122","author":"Leone","year":"2016","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1080\/14656566.2019.1667335","article-title":"Pharmacotherapeutic options for biliary tract cancer: Current standard of care and new perspectives","volume":"20","author":"Filippi","year":"2019","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_17","first-page":"420","article-title":"Chemotherapy with gemcitabine plus cisplatin in patients with advanced biliary tract carcinoma at Chang Gung Memorial Hospital: A retrospective analysis","volume":"35","author":"Wu","year":"2012","journal-title":"Chang. Gung Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1016\/j.celrep.2017.06.008","article-title":"Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles","volume":"19","author":"Farshidfar","year":"2017","journal-title":"Cell Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2019.06.003","article-title":"FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma","volume":"78","author":"Mahipal","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study","volume":"21","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Oh","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e000152","DOI":"10.1136\/esmoopen-2016-000152","article-title":"New molecular and immunotherapeutic approaches in biliary cancer","volume":"2","author":"Goldstein","year":"2017","journal-title":"ESMO Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Winkelmann, R., Schneider, M., Hartmann, S., Schnitzbauer, A.A., Zeuzem, S., Peveling-Oberhag, J., Hansmann, M.-L., and Walter, D. (2018). Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19051421"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41416-018-0199-2","article-title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","volume":"120","author":"Goeppert","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/278261a0","article-title":"T antigen is bound to a host protein in SV40-transformed cells","volume":"278","author":"Lane","year":"1979","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0092-8674(79)90293-9","article-title":"Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells","volume":"17","author":"Linzer","year":"1979","journal-title":"Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1128\/jvi.31.2.472-483.1979","article-title":"Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum","volume":"31","author":"Kress","year":"1979","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0042-6822(79)90250-2","article-title":"Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells","volume":"93","author":"Melero","year":"1979","journal-title":"Virology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0092-8674(79)90053-9","article-title":"Characterization of different tumor antigens present in cells transformed by simian virus 40","volume":"18","author":"Smith","year":"1979","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/312646a0","article-title":"Participation of p53 cellular tumour antigen in transformation of normal embryonic cells","volume":"312","author":"Eliyahu","year":"1984","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/312651a0","article-title":"Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53","volume":"312","author":"Jenkins","year":"1984","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/312649a0","article-title":"Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation","volume":"312","author":"Parada","year":"1984","journal-title":"Nature"},{"key":"ref_34","first-page":"313","article-title":"Meth A fibrosarcoma cells express two transforming mutant p53 species","volume":"3","author":"Eliyahu","year":"1988","journal-title":"Oncogene"},{"key":"ref_35","first-page":"531","article-title":"Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life","volume":"8","author":"Finlay","year":"1988","journal-title":"Mol. Cell. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1126\/science.2649981","article-title":"Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas","volume":"244","author":"Baker","year":"1989","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","article-title":"The p53 proto-oncogene can act as a suppressor of transformation","volume":"57","author":"Finlay","year":"1989","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.1978757","article-title":"Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms","volume":"250","author":"Malkin","year":"1990","journal-title":"Science"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1126\/science.2144363","article-title":"Presence of a potent transcription activating sequence in the p53 protein","volume":"249","author":"Fields","year":"1990","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0092-8674(91)90560-L","article-title":"Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication","volume":"65","author":"Bargonetti","year":"1991","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","article-title":"WAF1, a potential mediator of p53 tumor suppression","volume":"75","author":"Tokino","year":"1993","journal-title":"Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0092-8674(95)90412-3","article-title":"Tumor suppressor p53 is a direct transcriptional activator of the human bax gene","volume":"80","author":"Toshiyuki","year":"1995","journal-title":"Cell"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/0092-8674(92)90644-R","article-title":"The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation","volume":"69","author":"Momand","year":"1992","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/362857a0","article-title":"Oncoprotein Mdm2 Conceals the Activation Domain of Tumor Suppressor-P53","volume":"362","author":"Oliner","year":"1993","journal-title":"Nature"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1002\/j.1460-2075.1996.tb00919.x","article-title":"MDMX: A novel p53-binding protein with some functional properties of MDM2","volume":"15","author":"Shvarts","year":"1996","journal-title":"EMBO J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12009","DOI":"10.1073\/pnas.2030930100","article-title":"HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53","volume":"100","author":"Linares","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/378206a0","article-title":"Rescue of Embryonic Lethality in Mdm2-Deficient Mice by Absence of P53","volume":"378","author":"Jones","year":"1995","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.tcb.2010.01.009","article-title":"The p53 orchestra: Mdm2 and Mdmx set the tone","volume":"20","author":"Wade","year":"2010","journal-title":"Trends Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/351453a0","article-title":"The p53 tumour suppressor gene","volume":"351","author":"Levine","year":"1991","journal-title":"Nature"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","article-title":"Awakening guardian angels: Drugging the p53 pathway","volume":"9","author":"Brown","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: Origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/nrc3430","article-title":"MDM2, MDMX and p53 in oncogenesis and cancer therapy","volume":"13","author":"Wade","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Ong","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/ng.2273","article-title":"Exome sequencing of liver fluke-associated cholangiocarcinoma","volume":"44","author":"Ong","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2008.08.024","article-title":"Prognostic molecular markers in cholangiocarcinoma: A systematic review","volume":"45","author":"Briggs","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/1097-0142(20010401)91:7<1332::AID-CNCR1136>3.0.CO;2-4","article-title":"Differing rates of loss of DPC4 expression and of p53 overexpression among carcinomas of the proximal and distal bile ducts","volume":"91","author":"Argani","year":"2001","journal-title":"Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s004280000201","article-title":"Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: Relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features","volume":"437","author":"Horie","year":"2000","journal-title":"Virchows Arch."},{"key":"ref_61","first-page":"3961","article-title":"Expression of CD44 and MDM2 in cholangiocarcinoma is correlated with poor clinicopathologic characteristics","volume":"12","author":"Wattanawongdon","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41388-017-0060-8","article-title":"Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers","volume":"37","author":"Solomon","year":"2018","journal-title":"Oncogene"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kocik, J., Machula, M., Wisniewska, A., and Surmiak, E. (2019). Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists. Cancers, 11.","DOI":"10.3390\/cancers11071014"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","article-title":"Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer","volume":"7","author":"Glimelius","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbamcr.2014.10.003","article-title":"Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine","volume":"1853","author":"Fiorini","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2016.03.010","article-title":"Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival","volume":"151","author":"Wormann","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Dhayat, S.A., Mardin, W.A., Seggewi\u00df, J., and Str\u00f6se, A.J. (2015). MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143755"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1158\/1078-0432.CCR-19-3034","article-title":"TP53 Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial","volume":"26","author":"Sinn","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2019-125579","article-title":"APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myelodysplasies (GFM)","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","article-title":"APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells","volume":"6","author":"Mohell","year":"2015","journal-title":"Cell Death Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1158\/1535-7163.MCT-12-1166","article-title":"PRIMA-1Met\/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa","volume":"12","author":"Saha","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/cc.1.6.257","article-title":"Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function","volume":"1","author":"Dixon","year":"2002","journal-title":"Cell Cycle"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","article-title":"Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics","volume":"17","author":"Ma","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_76","first-page":"1842","article-title":"Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells","volume":"55","author":"Nagasawa","year":"1995","journal-title":"Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2174\/157488410791498824","article-title":"Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents","volume":"5","author":"Leijen","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1158\/0008-5472.CAN-13-3604","article-title":"CBP-93872 inhibits NBS1-mediated ATR activation, abrogating maintenance of the DNA double-strand break-specific G2 checkpoint","volume":"74","author":"Hirokawa","year":"2014","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"146282","DOI":"10.1155\/2015\/146282","article-title":"Targeting the Mitotic Catastrophe Signaling Pathway in Cancer","volume":"2015","year":"2015","journal-title":"Mediat. Inflamm."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.molonc.2011.07.002","article-title":"Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs","volume":"5","author":"Toledo","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: The checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"Sorensen","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1667\/0033-7587(2002)158[0084:HUPSCW]2.0.CO;2","article-title":"7-Hydroxystaurosporine (UCN-01) preferentially sensitizes cells with a disrupted TP53 to gamma radiation in lung cancer cell lines","volume":"158","author":"Xiao","year":"2002","journal-title":"Radiat. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","article-title":"MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells","volume":"17","author":"Bridges","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5674","DOI":"10.18632\/oncotarget.2158","article-title":"Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970","volume":"5","author":"Hall","year":"2014","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","article-title":"MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts","volume":"17","author":"Rajeshkumar","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1535-7163.MCT-13-0424","article-title":"Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality","volume":"12","author":"Baturin","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","article-title":"Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4143\/crt.2018.526","article-title":"Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer","volume":"51","author":"Nam","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4143\/crt.2020.080","article-title":"Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer","volume":"52","author":"Nam","year":"2020","journal-title":"Cancer Res. Treat."},{"key":"ref_90","first-page":"16","article-title":"PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1182\/blood-2011-03-340323","article-title":"HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma","volume":"118","author":"Jones","year":"2011","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1146\/annurev-pathol-012414-040349","article-title":"The Roles of MDM2 and MDMX in Cancer","volume":"11","author":"Lokshin","year":"2016","journal-title":"Annu. Rev. Pathol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1073\/pnas.1203789109","article-title":"Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization","volume":"109","author":"Graves","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"E3445","DOI":"10.1073\/pnas.1303002110","article-title":"Stapled alpha-helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy","volume":"110","author":"Chang","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7150\/jca.32765","article-title":"Recombinant Dual-target MDM2\/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1\/TAK1\/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells","volume":"11","author":"Fan","year":"2020","journal-title":"J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10555-008-9127-x","article-title":"The type 2C phosphatase Wip1: An oncogenic regulator of tumor suppressor and DNA damage response pathways","volume":"27","author":"Lu","year":"2008","journal-title":"Cancer Metastasis Rev."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nchembio.1427","article-title":"Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction","volume":"10","author":"Gilmartin","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bjc.2017.433","article-title":"Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma","volume":"118","author":"Wu","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1535-7163.MCT-15-0651","article-title":"Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1\/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner","volume":"15","author":"Esfandiari","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"14458","DOI":"10.18632\/oncotarget.7363","article-title":"Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3","volume":"7","author":"Pechackova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00109-017-1536-2","article-title":"WIP1 phosphatase as pharmacological target in cancer therapy","volume":"95","author":"Pechackova","year":"2017","journal-title":"J. Mol. Med. (Berl.)"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/11\/1474\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:46Z","timestamp":1760178406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/10\/11\/1474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":102,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["biom10111474"],"URL":"https:\/\/doi.org\/10.3390\/biom10111474","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}